 16 antibody therapeutics were granted a first approval in 2023, while 50 product candidates including innovative bispecific antibodies and antibody drug conjugates are under consideration for marketing applications or forecast to enter regulatory review by the end of 2024. The approval success rates for antibody therapeutics range from 14 to 32%, with higher rates associated with non-cancer indications, indicating that biopharmaceutical industry development efforts are robust and increasingly successful. This article was authored by Silvia Crescioli, Helen Kaplan, Alicia Chenoweth, and others.